ROIVANT SCIENCES LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.9 USD | -0.37% |
|
+4.41% | -2.94% |
| Apr. 05 | Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit | MT |
| Apr. 04 | Moderna Suffers Setback in Lawsuit by Arbutus | MT |
Presenter SpeechPaul Davis (Executives)Great. Good morning, [Foreign Language], and welcome to...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Roivant Sciences Ltd. is a commercial-stage biopharmaceutical company that seeks to improve the lives of patients by accelerating the development and commercialization of medicines that matter. The Companyâs pipeline is focused on inflammation and immunology and includes VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; batoclimab and IMVT-1402, fully human monoclonal antibodies targeting the neonatal Fc receptor (FcRn) in development across several IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody in development for ulcerative colitis and Crohnâs disease, in addition to various other therapies in various stages of clinical development. The Company advances its pipeline by creating nimble subsidiaries or Vants to develop and commercialize its medicines and technologies. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
Sector
Pharmaceuticals
Calendar
2024-06-25
- Q4 2023 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
10.9
USD
Average target price
16.08
USD
Spread / Average Target
+47.52%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -2.94% | 8.82B | |
| +25.61% | 672B | |
| +25.87% | 570B | |
| -5.24% | 360B | |
| +16.49% | 321B | |
| +8.28% | 300B | |
| +7.09% | 217B | |
| -9.12% | 204B | |
| +5.01% | 199B | |
| -8.75% | 149B |
- Stock Market
- Equities
- ROIV Stock
- News Roivant Sciences Ltd.
- Transcript : Roivant Sciences Ltd. - Analyst/Investor Day
